Kids’ Covid Vaccinations Plummet as U.S. Considers Shots for Younger ChildrenÂ
(Bloomberg) -- Covid-19 vaccinations among children ages 5-11 have fallen to the lowest levels since the shots were first approved, a sign that parental enthusiasm for the shots may be running low even as authorities consider expanding the shots to even younger children.
The seven-day average of first doses fell to about 37,062 on Jan. 28, marking the slowest one-week period since the government approved the vaccines for those children on Nov. 2, according to U.S. Centers for Disease Control and Prevention data. Just 31% of kids 5-11 have gotten a shot, compared with 75% of the total population.
First doses are declining among all age groups, but in most, that's because so many people have already had one. For children -- and young ones in particular -- there's clearly an enthusiasm gap, as parents weigh data showing that the virus itself is generally much less severe for them.
Pfizer Inc. and partner BioNTech SE have started to submit data to U.S. regulators as they seek approval for vaccines in kids 6 months through 4 years old. In December, the companies published data showing mixed effectiveness from two doses of the vaccine in younger kids. The companies said then that they would study a third dose and that if successful, they would seek a U.S. emergency authorization in the first half of 2022.
Either way, the younger the kids are, the less inclined parents seem to be to rush out for shots. Comparing uptake from the day the vaccines were first made available for each group, the 5-11 cohort has been much slower to get the shots than kids 12-15, who were approved May 12.
To be sure, the data from older kids show the first 90 days doesn't necessarily determine the success of the vaccination campaign. Inoculations in that group re-accelerated about 100 days after vaccine clearance, with the start of school and the onset of the colder-weather wave. But with the school year now in full swing and omicron receding, it's not clear that the same factors will come into play with the younger kids.
With adults, the story is different. According to a Jan. 11-23 survey of 1,536 adults for KFF Covid-19 Vaccine Monitor, the U.S. is very close to reaching maximum vaccine penetration, short of some dramatic change of heart among the hesitant or a major policy change. The latter would seem near impossible after the Supreme Court last month blocked President Joe Biden's effort to instate a vaccine-or-test rule for large companies.
The lion's share of adults who want one have gotten at least their first shot. The KFF survey shows that among those who shun vaccines, 14% will never get one, 3% will do so only if required to for work or school and 4% will wait and see.Â
Over time, the survey has suggested that many of the wait-and-see respondents eventually got the shot. But the “definitely not” and “only if required” groups have hardly budged since March 2021.
Vaccines have proved highly effective and blunted severe outcomes from Covid-19 in the U.S. In December, age-adjusted data show that unvaccinated adults were 16 times more likely to be hospitalized than people with at least two shots. Likewise, hospitalization rates were eight times higher for unvaccinated adolescents ages 12-17 versus their fully vaccinated peers. Data were not available for younger kids.
©2022 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.